Table 3.
Scientific design characteristics by TA and indication (Phase II and III only)
| Means (Coefficients of Variation) | Oncology | Non-oncology | Rare diseases | Non-rare diseases |
|---|---|---|---|---|
| Total Endpoints | 15.3 (0.49) | 21.4 (0.58) | 12.9 (0.46) | 21.2 (0.56) |
| Total Eligibility Criteria | 29.8 (0.33) | 31.0 (0.37) | 28.9 (0.38) | 31.1 (0.36) |
| Number of Distinct Procedures | 33.3 (0.45) | 34.3 (0.32) | 38.1 (0.50) | 33.3 (0.32) |
| Total Procedures Performed | 315.0 (0.93) | 243.0 (1.09) | 301.6 (1.14) | 255.6 (1.02) |
| Non-Core Procedures (% of Total) | 24.1% (0.82) | 24.9% (0.74) | 14.0% (0.83) | 26.4% (0.72) |
| Total Protocol Pages | 125.2 (0.23) | 107.5 (0.39) | 115.3 (0.18) | 110.8 (0.39) |
| Total Case Report Form Pages | 175.8 (0.84) | 168.7 (0.84) | 244.0 (0.74) | 158.7 (0.83) |
| Total Datapoints Collected | 2,563,973 (2.13) | 2,732,132 (1.60) | 1,599,282 (2.69) | 2,908,916 (1.59) |
| Total Data Sources | 3.9 (0.45) | 4.2 (0.37) | 4.2 (0.33) | 4.1 (0.41) |